Abstract Library

#4147 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Introduction: Cell-free DNA (cfDNA) 5-hydroxymethylcystosine (5hmC) analysis, a novel epigenomic technology, can detect changes in tumor gene expression and regulation in liquid biopsies.

Conference:

Presenting Author:

Authors: Sponheim J, Wong C, Thiis-Evensen E, Coruh C, Ning Y,

Keywords: [177Lu]Lu-DOTA-TATE, Lutathera, Peptide Receptor Radionuclide Therapy, Radioligand Therapy, Pancreatic Neuroendocrine Tumor, Biobank, 5-Hydroxymethylation,

#4014 Network pharmacology reveal the mechanism of Cordycepin and neuroendocrine tumors

Introduction: Patients with advanced neuroendocrine tumors (NETs) have few treatment options and poor prognosis. Cordycepin is a natural compound originally isolated from Cor­dyceps militaris. It has the potential to treat cancer by regulating multiple cellular signaling pathways. However, its anticancer effect and pharmacological mechanism in NETs have not been clarified.

Conference:

Presenting Author:

Authors: Liu M, Yan L, Tang Q,

Keywords: Cordycepin, neuroendocrine tumor, network pharmacology, enrichment analysis, Chinese medicine,

#3876 Comprehensive characterization of the NET methylome

Introduction: The methylome holds great promise for biomarker discovery in neuroendocrine tumors (NETs), as changes in DNA methylation allow differentiation into relevant subgroups and reveal tissue of origin. However, a comprehensive characterization of the NET methylome is lacking, hampering biological insight and meaningful biomarker selection.

Conference:

Presenting Author: Mariën L

Authors: Mariën L, Ibrahim J, Cremers T, Lybaert W, Prenen H,

Keywords: neuroendocrine tumor, DNA methylation, pathway analysis, biomarker selection,

#3832 Mutational profiling of pNETs and pNECs indicates implication of chromatin epigenetic modification

Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are classified as carcinomas (pNECs), and tumors (pNETs). Their handling is challenging and understanding their carcinogenesis process including genetic-epigenetic relations is crucial for their clinical management.

Conference:

Presenting Author: Angelioudaki I

Authors: Angelioudaki I, Koniaris E, Kataki A, Loukas Y, Thodi G,

Keywords: Neuroendocrine Tumor, Neuroendocrine Carcinoma, Pancreas, Next Generation Sequencing, Epigenetics,

#3796 The effect of pseudohypoxia on the immune microenvironment of pancreatic neuroendocrine neoplasms (PanNEN)

Introduction: Pancreatic neuroendocrine tumors may develop sporadically or as part of an inherited disease, such as von Hippel-Lindau (VHL). VHL disease is caused by a germline pathogenic variant in the VHL gene encoding VHL protein (pVHL). Hypoxia inducible factor (HIF) is responsible for cellular oxygen supply. Its degradation is mediated in normoxic states via ubiquitination and inhibited by pVHL. Hence, pVHL deficiency leads to pseudohypoxia due to HIF overexpression. Several studies suggested immunomodulatory role for HIF in kidney cancer.

Conference:

Presenting Author:

Authors: Solomon Chmelnik A, Telerman A, Tirosh A,

Keywords: Pancreatic neuroendocrine tumor, VHL, DNA methylation, Immune cells, PD-L1,